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Evaluation of a Multiplexed Bead Assay for Assessment
of Epstein-Barr Virus Immunologic Status
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Currently, serological assays using either indirect immunofluorescence assay or enzyme-linked immunosor-
bent assay (ELISA) are performed to evaluate the status of Epstein-Barr virus (EBV) infection in humans.
Although these methods are reliable, they are limited to testing an antibody response to a single viral antigen
per reaction, thus necessitating a panel of assays to complete the evaluation. In contrast, a new bead-based
method (BioPlex 2200; Bio-Rad Laboratories, Hercules, Calif.) can analyze the humoral response to multiple
antigens in a single tube. This approach potentially reduces overall cost, turnaround time, and sample volume.
The aim of this study was to evaluate the multiplexed EBV serologic assays performed on the BioPlex 2200
platform compared to results of conventional heterophile and ELISA-based assays. A total of 167 nonconsec-
utive, stored serum samples from adult and pediatric patients submitted for EBV serologic studies were used
in the evaluation. Concordance between results generated by the BioPlex 2200 system and conventional assays
was calculated. The anti-EA-D assay had the lowest concordance at 91%. The BioPlex 2200 system showed 97%
agreement with conventional heterophile and anti-nuclear antigen assays and 92% agreement with the anti-
VCA IgG and immunoglobulin M assays. Agreement between the BioPlex 2200 system and conventional testing
was 92% with respect to categorization of acute versus nonacute EBV disease. The correlation between these
two systems with regard to assignment into one of four categories of EBV status was also good (82%). In sum-
mary, there is excellent correlation between contemporary EBV serologic testing and the BioPlex 2200 system.
Epstein-Barr virus (EBV), a member of the family of human
herpesviruses, infects up to 95% of adults worldwide (13). In
most populations, EBV infection is generally established dur-
ing childhood, usually with little or no sequelae (12). However,
infection in an adolescent or adult patient not exposed to the
virus in early childhood often leads to infectious mononucle-
osis, the most severe acute form of EBV-related disease. In
addition, evidence of EBV infection has been demonstrated in
patients with a wide variety of benign and malignant lesions,
including Burkitt’s lymphoma and nasopharyngeal carcinoma,
and has been associated with the development of B-cell lym-
phoproliferative disease in patients who are post-solid organ or
hematopoietic stem cell transplantation (10).
The diagnosis of acute EBV infection can be challenging
since the symptoms are typically protean, resembling those of
other viral infections. Although the presence of atypical lym-
phocytes on a peripheral smear supports the diagnosis of in-
fectious mononucleosis, these are not universally detectable.
Furthermore, because of the impracticality of EBV culture and
the high prevalence of EBV in the population, specific viral
detection by culture or PCR is not frequently used. Alterna-
tively, the detection of heterophile antibodies and specific an-
tibodies against EBV antigens has proven useful in the diag-
nosis of acute EBV infection, especially in cases with a high
index of suspicion and a lack of atypical lymphocytes.
There are four basic categories of EBV status into which
patients can be divided by serology. These include patients
with no history of infection, patients who are acutely infected,
patients with evidence of a prior or remote infection, and
patients with reactivation of latent virus (14). Anti-EBV serol-
ogy, in combination with heterophile antibody testing, has
been used to categorize patients in this manner, and the clas-
sification of patients based on the pattern of antibody re-
sponses has been reviewed elsewhere (9, 13, 14). Briefly, acute
disease is suggested when immunoglobulin M (IgM) antibodies
to the viral capsid antigen (VCA) are detected. The presence
of heterophile antibodies and/or IgG antibodies to the D com-
ponent of the EBV early antigen (EA-D) further supports the
diagnosis of acute infection. In patients with a prior or remote
infection, anti-VCA IgG and IgG antibodies to the EBV nu-
clear antigen (NA) are typically observed. The anti-VCA IgG
antibodies slowly rise during acute infection but persist for life.
In contrast, the anti-VCA IgM and anti-EA-D IgG antibodies
rapidly decline as the patient recovers and are typically unde-
tectable after 12 months (8, 13, 14). Patients who have reacti-
vated latent virus will likely have evidence of past infection,
e.g., anti-VCA IgG and anti-NA IgG, but also one or more
markers of acute infection such as anti-VCA IgM. Because
patients recovering from a recent acute infection might have
antibody profiles similar to those with reactivated virus, it is
sometimes difficult to distinguish these two groups of patients
based on serology alone. In addition to patients who present
with a possible acute infection, EBV serology is often per-
formed on patients being evaluated for solid-organ or bone
marrow transplant (10).
At present, the humoral response to EBV infection is com-
monly evaluated using indirect immunofluorescence assay
(IFA) or enzyme-linked immunosorbent assay (ELISA)-based
formats. According to a 2003 survey of laboratories accredited
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by the College of American Pathologists, ELISA-based meth-
ods are now the most widely used (2). Furthermore, ELISA
methods are well characterized and are considered to be the
reference laboratory methods (3, 5, 7, 14, 15). Recently, Bio-
Rad Laboratories (Hercules, Calif.) introduced a new method
for the detection of antibodies to EBV (BioPlex 2200). The
instrument combines Lab-Map multi-analyte profiling technol-
ogy (Luminex, Austin, Tex.) (6) with unique antigen-coated
fluoromagnetic bead chemistry and versatile software. Briefly,
dyed (fluorescent) bead sets, each of which is coated with a
different, specific EBV antigen, are mixed with diluted patient
sample. After incubation and a wash cycle, an anti-human IgG
or IgM antibody conjugated with phycoerythrin (PE) is added.
The instrument can then identify beads based on the fluores-
cence of the dyes and quantitate antibody on each bead based
on the fluorescence of the PE. This is a robust system that can
assess the response to multiple, independent antigens in a
single incubation (multiplex). It has a number of potential
advantages over conventional microtiter plate serologic assays,
including a fully automated random access platform with min-
imal user interaction. Furthermore, common test groupings,
such as the assays performed to evaluate EBV serologic status
or ToRCH testing, can be performed in one tube. This strategy
can potentially lower cost, minimize aliquot errors, and reduce
turnaround time and sample requirements (5 l).
In the present study, the EBV assays on the BioPlex 2200
system were evaluated by comparing them to a conventional
rapid card assay for the detection of heterophile antibodies
and ELISA-based assays for the detection of anti-VCA IgG
and IgM, anti-NA IgG, and anti-EA-D IgG antibodies. In
addition, the agreement between the two systems in categoriz-
ing patients by EBV status was assessed.
(These findings were presented in part at the American
Association of Clinical Chemistry Annual Meeting in July 2004.)
MATERIALS AND METHODS
Patient samples. A total of 167 leftover serum samples sent to the laboratory
for physician-ordered EBV testing between October 2002 and September 2003
were evaluated. The sample population was designed to include a mix of adults
and children (21 years of age), as well as a mix of transplant patients and
individuals being evaluated for acute EBV infections. Twenty-three of the pa-
tients were selected because of positive heterophile and/or positive anti-VCA
IgM serology in order to increase the possible number of patients with acute
EBV disease. The present study was approved by the Washington University
Institutional Review Board for Clinical Studies.
EBV testing. Captia (Trinity Biotech, Jamestown, N.Y.) EBV anti-VCA IgG
and Wampole (Wampole Laboratories, Cranbury, N.J.) EBV anti-VCA IgM,
anti-EA IgG, and anti-NA IgG analyses were performed as described in the
manufacturers’ package inserts on the Dynex DSX (Dynex Laboratories, Chan-
tilly, Va.) automated platform. Briefly, diluted patient serum was incubated (30
min for VCA-IgM and 20 min for EA-IgG, NA-IgG, and VCA-IgG) with anti-
gen-bound microtiter plates. Antigen-antibody complexes bound to the plate
were then incubated with horseradish peroxidase-conjugated goat anti-human
IgG or IgM (30 min for IgM and 20 min for other antibodies) and developed (10
min) with tetramethylbenzidine. The reactions were stopped with H2SO4, and
color was spectrophotometrically detected at 450 nm. Samples used for IgM
detection were treated to remove excess IgG with goat or sheep anti-human IgG.
The antigen for the IgM anti-VCA kit is affinity-purified VCA (gp125). The
antigen for IgG anti-VCA is purified recombinant VCA (47-kDa fusion protein
including 53 amino acids from the C terminus of p18). EA-D antigen is a
recombinant protein derived from the carboxy terminus of the EA-D gene,
representing 200 codons. NA-1 antigen is a recombinant protein derived from
the carboxy terminus of the NA-1 gene, also representing 200 codons.
The Status Mono (LifeSign LLC, Somerset, N.J.) heterophile antibody assay
was performed as described in the manufacturer’s package insert. Briefly, patient
serum was placed on the test card by using the supplied capillary tube. Two to
three drops of developer solution (phosphate-buffered saline with 0.2% sodium
azide) were then added to the same well, and the cartridge was allowed to
develop for 8 min. The device contains a membrane strip coated with bovine
erythrocyte extract (test lane) and a pad impregnated with the monoclonal
mouse anti-human IgM antibody-dye conjugate in a protein matrix. A positive
result was reported if a line appeared in the test lane and in the internal control
lane. A single line in the control lane only was considered negative.
The five assays were also performed by using the Bio-Rad BioPlex 2200
system. These assays were carried out by the manufacturer. At that time, the
assays were experimental and not yet available commercially. Market introduc-
tion after U.S. Food and Drug Administration clearance is expected in late 2004.
The manufacturer was blinded to the ELISA and heterophile test results. Briefly,
two sets of incubations were performed for each sample: one for the IgG assays
and one for the IgM assays. Colored beads coated with the Escherichia coli-
derived recombinant VCA (40-kDa), EA-D (28-kDa), or NA-1 (28- and 45-kDa)
antigens were mixed together, along with the patient sample and diluent and
then allowed to incubate at 37°C for 20 min. After a wash cycle, anti-human IgG
antibody conjugated to PE was added to the dyed beads and allowed to incubate
at 37°C for 10 min. After removal of excess conjugate, the bead mixture was
passed through the detector that identifies the beads based on the fluorescence
of the dyes. The amount of antibody bound to the bead was determined by the
fluorescence of PE. Raw data were initially measured as the relative fluorescence
intensity and then converted to the fluorescence ratio by using a predyed internal
standard bead. A series of calibrators were analyzed with the patient samples to
convert fluorescence ratio to international units per milliliter. The heterophile
and VCA-IgM assays were performed in a separate incubation. In these IgM
assays, IgG antibodies were absorbed from the sample during mixing with the
beads. After this step, the subsequent procedure was the same as that for the IgG
incubation, except for the use of anti-human IgM instead of anti-IgG. The two
beads used in this incubation were coated with an E. coli-derived recombinant
VCA antigen (40 kDa) or horse erythrocyte stromal extract (heterophile antigen)
(4, 11). Two additional control beads were also included in all IgG and IgM
incubations. A serum verification bead and a blank bead were added to verify the
addition of serum to the reaction vessel and the absence of significant nonspecific
bead binding, respectively.
RESULTS
The patient population consisted of 125 children less than 21
years of age (75%) and 42 adults (25%). Forty-two of the
patients (9 children and 33 adults) were being evaluated prior
to solid-organ or hematopoietic stem cell transplant. A total of
28 patients had a clinical presentation and laboratory values
consistent with infectious mononucleosis. A total of 35 patients
had no evidence of previous exposure to EBV, whereas 67
patients had evidence of a past infection.
The BioPlex 2200 system was evaluated by assessing concor-
dance to standard ELISA and heterophile antibody assays. As
seen in Table 1, there is strong concordance between the two
systems for each test evaluated. The anti-EA IgG assay has the
lowest concordance at 91%, whereas the anti-VCA-IgG and
IgM assays both have concordances of 92%. The comparison
methods agree 97% of the time on the heterophile antibody
and anti-NA IgG assays.
The evaluation of EBV disease status does not rely on a
single antibody test but on the pattern of results obtained and
clinical presentation. Table 2 demonstrates a generally ac-
cepted algorithm for classifying patients into an EBV status via
serologic profile (5, 13, 14). Using this table, each patient was
assigned an EBV status based on results of the conventional
tests. This diagnosis was compared to a diagnosis derived from
Table 2 and results from the BioPlex 2200 testing.
As seen in Table 3, when the conventional and BioPlex 2200
methods are compared with respect to assignment of acute
versus nonacute EBV disease, the concordance is excellent
(92%). As shown in Table 4, the agreement between the two
VOL. 42, 2004 MULTIPLEXED EBV SEROLOGICAL ASSAY 4997
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systems with respect to assignment into one of four EBV se-
rologic categories is also good (82%).
DISCUSSION
Although there is no true “gold standard” for the diagnosis
of EBV-related disease, the evaluation of EBV serologic status
is often performed on patients who present with symptoms
consistent with infectious mononucleosis. In addition, patients
who are to undergo a solid-organ or hematopoietic stem cell
transplant are commonly tested due to the link between EBV
and posttransplant lymphoproliferative disease (10). The con-
ventional methods used to perform this testing are based on
ELISA and IFA. Although these methods are well character-
ized and reliable, they require an aliquot of sample and re-
agents for each antigen tested. Since the patient sample has to
be divided into aliquots multiple times, this can lead to so-
called “pour-off” errors. Furthermore, the turnaround time
and the cost of labor and materials rises proportionally with
each test performed. In order to circumvent these practical
issues, the idea of multiplexing EBV testing was developed (1).
The EBV assays on the BioPlex 2200 system are performed in
only two tubes, one for the IgG assays (EA, NA, and VCA-
IgG) and one for the IgM assays (heterophile and VCA-IgM),
allowing for all five tests to be performed with only two ali-
quots of reagents and patient sample.
As seen in Table 1, the agreement between the BioPlex 2200
and conventional assays for all five EBV assays was excellent
(91 to 97%). In fact, the agreement is higher than that ob-
served in another study comparing different ELISA and IFA
methods (5). This was especially evident with anti-EA IgG,
since the previous study compared ELISA to IFA methods,
whereas the present study compares two solid-phase immuno-
assays.
Although each test has good concordance, each individual
test disagreement could potentially lead to the assignment of a
different EBV disease status. As such, the concordance be-
tween the two systems in assigning one of four specific EBV
diagnoses was not as high (82%) as was observed for each
individual test. Nevertheless, the agreement between these two
systems in assigning a diagnosis is superior to that reported
between IFA and ELISA systems in two similar studies (3, 5).
As derived from Table 4, most of the disagreement in assigning
EBV status occurs when one is determining whether a patient
was previously infected or is in a reactivation or recovery stage.
This was due to the slightly lower concordance in anti-VCA
IgM and anti-EA-D IgG in this group of patients. This group
of disconcordant patients was examined closely; we found no
pattern with respect to the clinical presentation, to the results
of the other EBV serologic tests, or to the results of additional
serologic testing (such as with cytomegalovirus or herpes sim-
plex virus).
The most common use of EBV serology is to help distinguish
acute versus nonacute EBV disease, suggesting that this pa-
rameter is the most important in comparisons of the two assay
systems. When the BioPlex 2200 system and conventional as-
says are compared on this basis (Table 3), they show excellent
TABLE 1. Correlation of anti-EBV serology between the
BioPlex 2200 and conventional assay systems
Correlation (antibody)
and resultc
No. of sera that
gave a conventional-
assay result that was:
Concord-
ance
(%)
Positive Negative Equivocala
BioPlex 2200 (anti-VCA IgG)
vs Trinity ELISA
Positive 102 2 92
Negative 11 52
BioPlex 2200 (anti-VCA IgM)
vs Wampole ELISA
Positive 30 9 92
Negative 5 123
BioPlex 2200 (anti-NA)
vs Wampole ELISA
Positive 85 3 97
Negative 2 77
BioPlex 2200 (anti-EA)
vs Wampole ELISA
Positive 30 4 1 91
Negative 6 122 4
BioPlex 2200 (heterophile
antibody) vs Life Signb
Positive 26 2 97
Negative 3 136
a That is, borderline results in the Wampole anti-EA assay that could not be
determined as positive or negative.
b The Life Sign assay is a direct solid-phase immunoassay.
c Result of assay with the Bioplex 2200 system.
TABLE 2. Patterns of anti-EBV antibody production
associated with EBV disease stagea
EBV disease
stage
Productionb of:
Anti-VCA
IgG
Anti-VCA
IgM
Anti-NA-1
IgG
Anti-EA-D
IgG
Heterophile
antibody
Susceptible Neg Neg Neg Neg Neg
Primary acute Pos/Neg Pos Neg Pos Pos/Neg
Pos/Neg Pos Neg Neg Pos
Pos Neg Neg Pos Pos
Prior or remote Pos Neg Pos Neg Neg
Reactivation or
recovery
Pos Pos/Neg Pos Pos/Neg Pos/Neg
Pos Pos Neg Neg Neg
a Information derived from references 5 and 14.
b Pos, positive; Neg, negative; Pos/Neg, either positive or negative.
TABLE 3. Comparison of serological pattern interpretations
in determining acute EBV infection between the
BioPlex 2200 and conventional assay systems
Trinity/Wampole/LifeSign-
based diagnosis
Bio-Rad multi-analyte bead system-based
diagnosis (no. of sera)
Acute
infection
No acute
infectiona Unresolved
b Total
Acute infection 28 0 0 28
No acute infection 0 117 5 122
Unresolvedb 1 8 8 17
Total 29 125 13 167c
a Includes cases of prior or remote infection and reactivation, recovery, and
susceptible cases, as defined in Table 2.
b Unresolved samples have patterns of antibody reactivity that are not consis-
tent with any category listed in Table 2.
c The overall concordance was calculated as (28  117  8)/167  92%.
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concordance (92%). Furthermore, the disagreements in Table
3 are primarily in distinguishing nonacute patients from those
with unresolved serologic patterns. There is very little disagree-
ment in distinguishing acute from either nonacute or unre-
solved patients. In fact, there was only one patient classified by
either method as having an acute infection that was not clas-
sified as such by both methods. This patient had a bilateral lung
transplant 1 year prior to testing and was on immunosuppres-
sive therapy. She did not have classic infectious mononucleo-
sis-like symptoms, nor did she have atypical lymphocytes on
the peripheral smear. However, the EBV anti-VCA IgG and
IgM and anti-EA-D IgG were positive by the BioPlex 2200
testing, but only the anti-VCA IgG and EA-D were positive by
ELISA. There was no clear clinical evidence of infectious
mononucleosis in this case, nor is there a gold standard that
could be utilized to accurately diagnose EBV-related disease.
As such, it was not possible to determine which of the two
methods was correct with respect to the anti-VCA IgM results.
Most laboratories routinely offer only three of the five avail-
able EBV tests—the heterophile antibody test and the anti-
VCA IgM and IgG assays—since most patients can be properly
diagnosed by using these three antibodies. The assumptions
typically made are that patients who are anti-VCA-IgM or
heterophile positive have acute disease and those who are
positive for IgG and negative for IgM and heterophile had a
past infection but do not currently have disease. One problem
with these assumptions is evident in Table 2. With only the
three tests, patients who are VCA IgG and IgM positive and
heterophile negative would be diagnosed with acute-phase ill-
ness. However, these patients could potentially be classified
differently if all five tests were performed. For example, if a
patient with the VCA and heterophile pattern described above
were negative for both anti-NA-1 and anti-EA-D, then they
would be considered to be in a recovery stage of the illness (last
row of Table 2). This change in classification can have impli-
cations on long-term patient management, especially in neo-
natal and immunocompromised populations. Furthermore, if
the anti-NA-1 was positive, then the illness would be more
likely to be secondary to reactivation of latent virus, which
could be useful information for physicians monitoring trans-
plant patients (10). Ten patients within our population fit into
one of these two scenarios. Since the practical issues limiting
most centers to the three tests do not apply to the BioPlex 2200
system, all five tests can be routinely performed on each pa-
tient without an increase in labor, reagents, or sample require-
ments.
The BioPlex 2200 has been developed for high-throughput
analysis of autoimmune analytes, as well as for common sero-
logical markers. The advantages of this system are that it offers
full integration of sampling, antibody extraction, incubations,
washing, and detection. The processing rate is 100 specimens/h
(i.e., 300 EBV IgG test results or 200 EBV IgM/heterophile
test result/h). The disadvantages are that it is a closed system,
which limits its flexibility, and given the current menu, it is best
suited for only larger laboratories.
This report provides a comparison between the Bio-Rad
BioPlex 2200 and traditional ELISA-based assays. The two
systems show excellent test-by-test concordance and also ex-
cellent agreement in the diagnosis of acute EBV infection.
However, the BioPlex 2200 system offers practical advantages
that allow for rapid evaluation of all five EBV antibodies. This
can potentially yield laboratory benefits, as well as advantages
in the medical management of patients that may have EBV
infections.
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